CIK 0001812364 · Large accelerated filer
Relay Therapeutics, Inc.
Sign in to watch- Ticker
- RLAY
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-370-8837
- Business address
- 60 HAMPSHIRE STREET, CAMBRIDGE, MA, 02139
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $120,165,474
- in 11 filings, $3.7M under 10b5-1 plans
Net −$120,165,474. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 98 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-07-09 | Patel Sanjiv President and CEO | Sale | −18,639 | $3.57 | $67K | 765,288 |
| 2025-06-30 | Rahmer Peter See remarks | Grant or award | +5,000 | $2.94 | $15K | 395,081 |
| 2025-06-30 | Patel Sanjiv President and CEO | Grant or award | +5,000 | $2.94 | $15K | 826,667 |
| 2025-06-09 | Mazumdar Claire Director | Grant or award · Stock Option (Right to Buy) | +421,241 | 421,241 | ||
| 2025-06-06 | HILL LINDA A Director | Grant or award · Stock Option (Right to Buy) | +136,681 | 136,681 | ||
| 2025-06-06 | Borisy Alexis Director | Grant or award · Stock Option (Right to Buy) | +136,681 | 136,681 | ||
| 2025-06-06 | INGRAM DOUGLAS S Director | Grant or award · Stock Option (Right to Buy) | +136,681 | 136,681 | ||
| 2025-06-06 | Kathiresan Sekar Director | Grant or award · Stock Option (Right to Buy) | +136,681 | 136,681 | ||
| 2025-06-06 | Murcko Mark Director | Grant or award · Stock Option (Right to Buy) | +136,681 | 136,681 | ||
| 2025-06-06 | Rubin Jami Director | Grant or award · Stock Option (Right to Buy) | +136,681 | 136,681 | ||
| 2025-04-30 | Rahmer Peter See remarks | Sale | −10,739 | $3.00 | $32K | 390,081 |
| 2025-04-30 | Catinazzo Thomas Chief Financial Officer | Sale 10b5-1 | −12,943 | $3.00 | $39K | 355,376 |
| 2025-04-30 | Bergstrom Donald A President, R&D | Sale | −27,472 | $3.00 | $82K | 583,490 |
| 2025-04-30 | Adams Brian Chief Legal Officer | Sale | −12,943 | $3.00 | $39K | 391,385 |
| 2025-04-29 | Catinazzo Thomas Chief Financial Officer | Sale 10b5-1 | −3,558 | $3.23 | $11K | 368,319 |
| 2025-04-28 | Rahmer Peter See remarks | Sale | −1,364 | $3.17 | $4K | 400,820 |
| 2025-04-28 | Catinazzo Thomas Chief Financial Officer | Sale 10b5-1 | −1,709 | $3.17 | $5K | 372,858 |
| 2025-04-28 | Catinazzo Thomas Chief Financial Officer | Sale 10b5-1 | −981 | $3.17 | $3K | 371,877 |
| 2025-04-28 | Bergstrom Donald A President, R&D | Sale | −4,090 | $3.17 | $13K | 610,962 |
| 2025-04-28 | Adams Brian Chief Legal Officer | Sale | −1,644 | $3.17 | $5K | 404,328 |
Page 5 of 17 · 329 trades